News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
This article was originally published in The Gray Sheet
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.